Editas Medicine, a transformative genome editing company, today announced the publication of new data highlighting novel approaches to improve the specificity of CRISPR/Cas9 genome editing technology. The data are presented in two papers independently co-authored by company co-founders Keith Joung, M.D., Ph.D. and David Liu, Ph.D. in the current online edition of Nature Biotechnology.
Help employers find you! Check out all the jobs and post your resume.
